Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Walter J. Curran"'
Autor:
Ke Xu, Dongkyoo Park, Andrew T. Magis, Jun Zhang, Wei Zhou, Gabriel L. Sica, Suresh S. Ramalingam, Walter J. Curran, Xingming Deng
Publikováno v:
Molecular Cancer, Vol 18, Iss 1, Pp 1-16 (2019)
Abstract Background Lung cancer patients with KRAS mutation(s) have a poor prognosis due in part to the development of resistance to currently available therapeutic interventions. Development of a new class of anticancer agents that directly targets
Externí odkaz:
https://doaj.org/article/3f768d5575f04b929f12a8fef492e1de
Autor:
Ke Xu, Dongkyoo Park, Andrew T. Magis, Jun Zhang, Wei Zhou, Gabriel L. Sica, Suresh S. Ramalingam, Walter J. Curran, Xingming Deng
Publikováno v:
Molecular Cancer, Vol 19, Iss 1, Pp 1-1 (2020)
An amendment to this paper has been published and can be accessed via the original article.
Externí odkaz:
https://doaj.org/article/f371963b104a416b8665cfeb2193aa6b
Autor:
Andrew T. Magis, Xingming Deng, Wei Zhou, Dongkyoo Park, Jun Zhang, Walter J. Curran, Suresh S. Ramalingam, Ke Xu, Gabriel Sica
Publikováno v:
Molecular Cancer, Vol 18, Iss 1, Pp 1-16 (2019)
Molecular Cancer
Molecular Cancer
Background Lung cancer patients with KRAS mutation(s) have a poor prognosis due in part to the development of resistance to currently available therapeutic interventions. Development of a new class of anticancer agents that directly targets KRAS may
Autor:
Jun Zhang, Dongkyoo Park, Wei Zhou, Andrew T. Magis, Ke Xu, Xingming Deng, Walter J. Curran, Suresh S. Ramalingam, Gabriel Sica
Publikováno v:
Molecular Cancer, Vol 19, Iss 1, Pp 1-1 (2020)
Molecular Cancer
Molecular Cancer
Lung cancer patients with KRAS mutation(s) have a poor prognosis due in part to the development of resistance to currently available therapeutic interventions. Development of a new class of anticancer agents that directly targets KRAS may provide a m
Autor:
Paul B. Gilman, Xinglei Shen, Rita Axelrod, Albert S. DeNittis, Thomas J. Meyer, Joseph Treat, Walter J. Curran, Maria Werner-Wasik, Mitchell Machtay
Publikováno v:
Radiation Oncology, Vol 6, Iss 1, p 17 (2011)
Radiation Oncology (London, England)
Radiation Oncology (London, England)
Background This phase I study investigates the feasibility of carboplatin plus dose-dense (q2-week) pemetrexed given concurrently with radiotherapy (XRT) for locally advanced and oligometastatic non-small cell lung cancer (NSCLC). Methods Eligible pa
Autor:
Philip J. Tofilon, Arnab Chakravarti, Prakash Chinnaiyan, Amyn M. Rojiani, Walter J. Curran, Elizabeth Hammond, Minesh P. Mehta, K. Kian Ang, Meihua Wang, Hua Zhong Zhang
Publikováno v:
Radiation Oncology, Vol 3, Iss 1, p 32 (2008)
Radiation Oncology (London, England)
Radiation Oncology (London, England)
Background Nestin is an intermediate filament protein that has been implicated in early stages of neuronal lineage commitment. Based on the heterogeneous expression of nestin in GBM and its potential to serve as a marker for a dedifferentiated, and p